Advanced Development of Multivalent Filovirus Vaccines

Abstract

This contract supports advanced development of a of multivalent filovirus (Ebola and Marburg) vaccine through cGMP manufacturing with an option for a Phase 1 clinical trial. Additional options provide for large scale production, development of a lyophilized formulation and a Phase 2 clinical trial.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research and Development Contracts (N01)
• Project #: 272200800056C-0-0-1
• Application #: 7699973
• Project Start: 2008-09-30
• Project End: 2013-09-29
• Fiscal Year: 2008
• Total Cost: $13,496,364

Institution

• Name: Crucell Holland, Bv
• DUNS #: 415960780
• City: Leiden
• Country: Netherlands
• Zip Code: 2333 -CN